ZACKS·2026-03-13 08:31Core Insights - The Zacks Equity Research team has highlighted several stocks, including Oracle Corp., T-Mobile US, Inc., Gilead Sciences, Inc., National Research Corp., and C&F Financial Corp., in their recent Analyst Blog [1][2] Oracle Corp. (ORCL) - Oracle's shares have outperformed the Zacks Computer - Software industry over the past year, with a growth of 11.6% compared to the industry's 2.7% [4] - The company reported strong fiscal Q3 2026 results, with earnings and revenues exceeding estimates, driven by an 84% surge in cloud infrastructure revenues due to AI workload and multicloud demand [4] - Free cash flow for the trailing 12 months was negative $13.2 billion as Oracle continues to invest aggressively in data center build-outs [5] - Competition from hyperscalers poses a risk to margins, and the transition from license revenue to subscription models may lead to near-term earnings volatility [6] T-Mobile US, Inc. (TMUS) - T-Mobile's shares have underperformed the Zacks Wireless National industry over the past six months, declining by 10.1% compared to the industry's 1.6% [7] - The company faces challenges due to macroeconomic factors, market saturation, and high debt burden, which could impact its premium valuation [7] - Despite these challenges, T-Mobile has achieved industry-leading postpaid customer growth and a record-low churn rate, bolstered by its acquisition strategy [8] - The company's 2.5 GHz 5G spectrum provides competitive advantages in speed and coverage [9] Gilead Sciences, Inc. (GILD) - Gilead's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past six months, with a growth of 30.6% compared to 19.5% for the industry [10] - The company reported better-than-expected fourth-quarter results, driven by its market-leading HIV franchise, particularly Biktarvy and Descovy [10] - Gilead expects HIV sales to grow approximately 6% in 2026, with Biktarvy projected to have a CAGR of around 6% over the next three years [11] - The company is also developing additional HIV treatments and strengthening its oncology and virology franchises through collaborations [12] National Research Corp. (NRC) - National Research's shares have outperformed the Zacks Business - Information Services industry over the past six months, with a growth of 0.5% compared to a decline of 15.2% for the industry [13] - The company's Total Recurring Contract Value (TRCV) has risen for five consecutive quarters, reaching approximately $152 million by March 2026 [13] - New sales increased by approximately 86% in 2025, indicating improved commercial execution [14] - However, the company has faced declining revenues for three consecutive years, which poses execution risks if TRCV does not translate into growth [15] C&F Financial Corp. (CFFI) - C&F Financial's shares have outperformed the Zacks Banks - Southeast industry over the past six months, with a growth of 1.5% compared to a decline of 5.3% for the industry [16] - The company benefits from a diversified three-segment model that supports stable earnings and reduces reliance on any single revenue stream [16] - Core banking expansion is driving recurring income, while mortgage banking performance is improving as originations recover [17] - Key risks include margin pressure from interest-rate shifts and rising operating expenses [18]